PregnanTech

Preterm Birth Prevention

Health Tech & Life Sciences
Active
Seed Israel Founded 2017
Last updated 2026-06-18
Total raised
Last: 2026-01
Stage
Seed
Founded
2017
Headcount
8
HQ
Israel
Sector
Health Tech & Life Sciences

About

PregnanTech is developing the Lioness, a small, disposable device designed to maintain the natural resistance of the cervix in order to prevent preterm birth. The Lioness is positioned around the uterine cervix and behaves like a shock absorber, allowing transient shortening and dilation of the cervix during contractions and then restoring the cervix to its initial state when contractions subside. The device is inserted by a physician during an outpatient visit and removed at term. PregnanTech has conducted a range of successful preclinical studies and in 2019 began a clinical safety study of Lioness among non-pregnant women intended for hysterectomy. Initial findings demonstrate the significant potential inherent in the device. Professor Kypros Nicolaides, a preeminent obstetrician from Kings College Hospital in London, has expressed his interest in leading a first clinical trial in 2021 among pregnant women at risk of preterm birth. PregnanTech is part of the Trendlines Group.

Funding history · 5 rounds · — total

2026-01
Undisclosed
2023-02
Undisclosed
2020-08
Undisclosed
2020-01
Undisclosed

Q&A

What is PregnanTech's primary focus?
PregnanTech is focused on preterm birth prevention through the development of the Lioness device.
What is the Lioness device?
The Lioness is a small, disposable device developed by PregnanTech designed to maintain the natural resistance of the cervix to prevent preterm birth. It acts like a shock absorber around the uterine cervix.
When was PregnanTech founded?
PregnanTech was founded in January 2017.
How many employees does PregnanTech have?
PregnanTech has 1-10 employees.
Which investors participated in PregnanTech's February 2023 funding round?
In February 2023, 4T Ventures participated in a funding round for PregnanTech.
Which investor participated in PregnanTech's January 2026 funding round?
In January 2026, Longliv Ventures participated in a funding round for PregnanTech.
What is PregnanTech's current product stage?
PregnanTech's product, the Lioness, is currently in the clinical trial stage.
Where is PregnanTech headquartered?
PregnanTech is headquartered in Misgav Industrial Park, Tchelet Street 17, Israel.

Team · 2

Founder · Co-founder & CEO
LinkedIn ↗
Founder · Co-founder & CSO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Monitors
Technologies
Materials & SubstancesSilicon
Target customers
ConsumersDemographics & FamilyWomenHealthcare & Life SciencesHealthcareProvidersPatients
Business model
B2B

Highlights

1 Patents

Tags

femtechdoctorsdeliveryclinicspregnancygynecologywomen-healthhospitalswomenhealthcare-providersmedical-devices
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)